Skip to content
Research Article Open access CC BY 4.0

Efficacy and Safety of Fixed-Dose Combination of Efonidipine and Telmisartan in Stage II Hypertensive Patients: Results from Randomized Clinical Trial

Bhupesh Dewan, Siddheshwar Shinde, Shweta Kondekar

Cardiology and Angiology: An International Journal · pp. 24–35 · Published 28 Jan 2023

10.9734/ca/2023/v12i1309

Abstract

Aim: The aim of this study was to evaluate the anti-hypertensive efficacy of a fixed-dose combination (FDC) of Efonidipine 40 mg and Telmisartan 40 mg in Stage II hypertensive patients. Study Design:  Multicentric, randomized, double-blind, parallel, comparative Phase III clinical trial. Methodology: This clinical trial was conducted at six geographically distributed sites across India and enrolled 240 Stage II hypertensive patients. They were randomized into two groups in a ratio of 1:1 using computer-generated block randomization to receive E+T (FDC of Efonidipine 40 mg + Telmisartan 40mg) or C+T (FDC of Cilnidipine 10 mg + Telmisartan 40 mg) group intervention once daily for a period of 90 days. The study site staff, investigator and patients were blinded to the treatment allocation.  The primary endpoint of the study evaluated the mean reduction in sitting systolic BP (SBP) and diastolic BP (DBP) from baseline to day 90 whereas the secondary endpoints assessed were mean reduction in BP from baseline to day 30 & 60, patients achieving target BP (<140/90 mmHg) and the safety and tolerability of the investigational products based on the incidences of adverse events (AEs) reported.  Results: A total of 118 subjects were randomized to the E+T group wherein the mean (±SD) SBP and DBP at baseline was 167.25 ± 4.68/107.26 ± 5.19 mmHg. After 30 days of treatment with the E+T group, the mean reduction in SBP/DBP of 29.37/18.06 mmHg was observed whereas at Day 60 reduction of 38.55/22.69 mmHg was seen from the baseline. At Day 90, SBP/DBP decreased to 119.41±14.99/81.67±4.29 mmHg with a mean reduction of 47.94/25.89 mmHg in the E+T group. During the study period, the difference in systolic blood pressure between the treatments with E+T and C+T was -0.48 mmHg, with the two-sided 95% confidence interval (CI) ranging from -4.54 to 3.58 mmHg. The corresponding difference in diastolic blood pressure was -0.77 (95% CI: -2.60 to 1.06) mm Hg. The upper boundary of the 95% CI was below the margin of 10 mmHg, confirming the non-inferiority of E+T to C+T. A total of 92% of patients who had been assigned to E+T treatment achieved their target BP goal. Only one patient reported an adverse event with E+T treatment. No unexpected AEs were reported in the E+T group suggesting its good safety and tolerability. Overall, the E+T treatment was effective, safe and well-tolerated by the patients for 90 days. Conclusion: It was concluded that the FDC of Efonidipine 40 mg and Telmisartan 40 mg was efficacious in the management of Stage II hypertension.

Stage II hypertension calcium channel blocker angiotensin II receptor blocker Fixed-dose combination

References (27)

  1. 1 2018 ESC/ESH Guidelines for the management of arterial hypertension [DOI]
  2. 2 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults [DOI]
  3. 3 Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants [DOI]
  4. 4 High Blood Pressure and Cardiovascular Disease [DOI]
  5. 5 Noncommunicable diseases country profiles 2011.
  6. 6 Hypertension in India [DOI]
  7. 7 Trends in hypertension epidemiology in India [DOI]
  8. 8 Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents [DOI]
  9. 9 A Review on Telmisartan: A Novel, Long‐Acting Angiotensin II‐Receptor Antagonist [DOI]
  10. 10 Association between high blood pressure and long term cardiovascular events in young adults: systematic review and meta-analysis [DOI]
  11. 11 Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey [DOI]
  12. 12 Combination therapy in the treatment of hypertension [DOI]
  13. 13 Two-Drug Combinations as First-Step Antihypertensive Treatment [DOI]
  14. 14 Hypertension management 2011: optimal combination therapy [DOI]
  15. 15 Managing Hypertension Using Combination Therapy.
  16. 16 Regional estimates of noncommunicable diseases associated risk factors among adults in India: results from National Noncommunicable Disease Monitoring Survey [DOI]
  17. 17 Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment [DOI]
  18. 18 Current perspectives on combination therapy in the management of hypertension [DOI]
  19. 19 Fixed-dose combinations for hypertension [DOI]
  20. 20 Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect [DOI]
  21. 21 Efonidipine Hydrochloride: A Dual Blocker of L‐ and T‐Type Ca2+ Channels [DOI]
  22. 22 Rational approaches to the treatment of hypertension: drug therapy—monotherapy, combination, or fixed-dose combination? [DOI]
  23. 23 Telmisartan/Amlodipine [DOI]
  24. 24 Fixed-Dose Combinations as Initial Therapy for Hypertension [DOI]
  25. 25 Current status of calcium antagonists in Japan [DOI]
  26. 26 Fixed-dose combination therapy to improve hypertension treatment and control in Latin America [DOI]
  27. 27 Effects of Efonidipine, an L- and T-type Calcium Channel Blocker, on the Renin-Angiotensin-Aldosterone System in Chronic Hemodialysis Patients [DOI]

Cited by 3

Consensus Statements from the Nephrologists Alliance on Calcium Channel Blockers with Special Emphasis on Cilnidipine and Its Role in the Management of Hypertension in Chronic Kidney Disease

Ashok Kirpalani, D. Chafekar, S. Bansal · Journal of Association of Physicians of India · 2026

Showing 1 of 3 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

57

Page views

0

PDF downloads

27

Outbound clicks

3

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.